Key Takeaways:
Goldman Sachs revises its forecast for the anti-obesity drug market down to $95 billion by 2030. Eli Lilly’s one-year average target price suggests a potential upside of 36.07%. The GF Value estimate indicates a significant upside potential of 65.86% for Eli Lilly and Co (LLY, Financial).Goldman Sachs’ Market Forecast Adjustment
Goldman Sachs has revised its prediction for the anti-obesity drug market, adjusting it downward to $95 billion by the year 2030. This is a notable decrease from an earlier estimate of $130 billion. This revision impacts major pharmaceutical players such as Eli Lilly (LLY) and is attributed to changes in drug pricing, the extent of insurance coverage, and shifts in patient market segmentation.
Wall Street Analysts’ Forecast for Eli Lilly (LLY, Financial)
Wall Street analysts have provided a range of one-year price targets for Eli Lilly and Co (LLY, Financial). Based on insights from 26 analysts, the average target price is projected at $971.17. This includes a high estimate of $1,190.00 and a low estimate of $675.00. These figures suggest a potential upside of 36.07% from the current trading price of $713.71. For further details, explore the Eli Lilly and Co (LLY) Forecast page.
Furthermore, consensus from 30 brokerage firms provides Eli Lilly and Co (LLY, Financial) with an average brokerage recommendation of 1.9, which signifies an “Outperform” status. The rating system operates on a scale from 1 to 5, where 1 indicates a Strong Buy and 5 represents a Sell.
GuruFocus Valuation Insights
The GF Value estimate for Eli Lilly and Co (LLY, Financial) in one year stands at $1183.74, indicating an impressive upside potential of 65.86% from the current price of $713.71. GF Value represents GuruFocus’ estimation of the stock’s fair trading value, derived from historical trading multiples, past business growth, and future performance projections. For more extensive data, visit the Eli Lilly and Co (LLY) Summary page.